{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,3]],"date-time":"2025-08-03T22:59:18Z","timestamp":1754261958883,"version":"3.37.3"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2018,6,18]],"date-time":"2018-06-18T00:00:00Z","timestamp":1529280000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Colorectal Dis"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1007\/s00384-018-3098-3","type":"journal-article","created":{"date-parts":[[2018,6,18]],"date-time":"2018-06-18T16:29:25Z","timestamp":1529339365000},"page":"1215-1223","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["The influence of tumour site on prognosis in metastatic colorectal carcinomas with primary tumour resection"],"prefix":"10.1007","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2676-9486","authenticated-orcid":false,"given":"Susanne","family":"Merkel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vera S.","family":"Schellerer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Axel","family":"Wein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabine","family":"Semrau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carol","family":"Geppert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonas","family":"G\u00f6hl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Werner","family":"Hohenberger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Klaus","family":"Weber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Gr\u00fctzmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,6,18]]},"reference":[{"issue":"8","key":"3098_CR1","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1093\/annonc\/mdx175","volume":"28","author":"D Arnold","year":"2017","unstructured":"Arnold D, Lueza B, Douillard JY, Peeters M, Lenz HJ, Venook A, Heinemann V, Van Cutsem E, Pignon JP, Tabernero J, Cervantes A, Ciardiello F (2017) Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials. Annals of oncology : Official Journal of the European Society for Medical Oncology 28(8):1713\u20131729. \n                    https:\/\/doi.org\/10.1093\/annonc\/mdx175","journal-title":"Annals of oncology : Official Journal of the European Society for Medical Oncology"},{"key":"3098_CR2","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1001\/jamaoncol.2016.3797","volume":"3","author":"S Tejpar","year":"2016","unstructured":"Tejpar S, Stintzing S, Ciardiello F, Tabernero J, Van Cutsem E, Beier F, Esser R, Lenz HJ, Heinemann V (2016) Prognostic and predictive relevance of primary tumor location in patients with RAS wild-type metastatic colorectal Cancer: retrospective analyses of the CRYSTAL and FIRE-3 trials. JAMA Oncology 3:194. \n                    https:\/\/doi.org\/10.1001\/jamaoncol.2016.3797","journal-title":"JAMA Oncology"},{"issue":"10","key":"3098_CR3","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1016\/S1470-2045(16)30269-8","volume":"17","author":"S Stintzing","year":"2016","unstructured":"Stintzing S, Modest DP, Rossius L, Lerch MM, von Weikersthal LF, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, Heintges T, Lerchenmuller C, Kahl C, Seipelt G, Kullmann F, Stauch M, Scheithauer W, Held S, Giessen-Jung C, Moehler M, Jagenburg A, Kirchner T, Jung A, Heinemann V, FIRE-3 investigators (2016) FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial. Lancet Oncol 17(10):1426\u20131434. \n                    https:\/\/doi.org\/10.1016\/S1470-2045(16)30269-8","journal-title":"Lancet Oncol"},{"key":"3098_CR4","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.ejca.2017.12.014","volume":"91","author":"KL Rooijen van","year":"2018","unstructured":"van Rooijen KL, Shi Q, Goey KKH, Meyers J, Heinemann V, Diaz-Rubio E, Aranda E, Falcone A, Green E, de Gramont A, Sargent DJ, Punt CJA, Koopman M (2018) Prognostic value of primary tumour resection in synchronous metastatic colorectal cancer: individual patient data analysis of first-line randomised trials from the ARCAD database. Eur J Cancer 91:99\u2013106. \n                    https:\/\/doi.org\/10.1016\/j.ejca.2017.12.014","journal-title":"Eur J Cancer"},{"issue":"4","key":"3098_CR5","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1111\/j.1463-1318.2008.01735.x","volume":"11","author":"W Hohenberger","year":"2009","unstructured":"Hohenberger W, Weber K, Matzel K, Papadopoulos T, Merkel S (2009) Standardized surgery for colonic cancer: complete mesocolic excision and central ligation\u2014technical notes and outcome. Colorectal disease : the official Journal of the Association of Coloproctology of Great Britain and Ireland 11(4):354\u2013364; discussion 364-355. \n                    https:\/\/doi.org\/10.1111\/j.1463-1318.2008.01735.x","journal-title":"Colorectal disease : the official Journal of the Association of Coloproctology of Great Britain and Ireland"},{"issue":"9","key":"3098_CR6","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1002\/bjs.10183","volume":"103","author":"S Merkel","year":"2016","unstructured":"Merkel S, Weber K, Matzel KE, Agaimy A, Gohl J, Hohenberger W (2016) Prognosis of patients with colonic carcinoma before, during and after implementation of complete mesocolic excision. Br J Surg 103(9):1220\u20131229. \n                    https:\/\/doi.org\/10.1002\/bjs.10183","journal-title":"Br J Surg"},{"issue":"10","key":"3098_CR7","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1002\/bjs.1800691019","volume":"69","author":"RJ Heald","year":"1982","unstructured":"Heald RJ, Husband EM, Ryall RD (1982) The mesorectum in rectal cancer surgery\u2014the clue to pelvic recurrence? Br J Surg 69(10):613\u2013616","journal-title":"Br J Surg"},{"issue":"12","key":"3098_CR8","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.1200\/JCO.2008.20.2879","volume":"27","author":"DJ Sargent","year":"2009","unstructured":"Sargent DJ, Kohne CH, Sanoff HK, Bot BM, Seymour MT, de Gramont A, Porschen R, Saltz LB, Rougier P, Tournigand C, Douillard JY, Stephens RJ, Grothey A, Goldberg RM (2009) Pooled safety and efficacy analysis examining the effect of performance status on outcomes in nine first-line treatment trials using individual data from patients with metastatic colorectal cancer. J Clin Oncol Off J Am Soc Clin Oncol 27(12):1948\u20131955. \n                    https:\/\/doi.org\/10.1200\/JCO.2008.20.2879","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"3098_CR9","volume-title":"TNM classification of malignant tumours","author":"JD Brierly","year":"2017","unstructured":"Brierly JD, Gospodarowicz MK, Wittekind C (2017) TNM classification of malignant tumours, 8th edn. Wiley Blackwell, Oxford","edition":"8"},{"key":"3098_CR10","doi-asserted-by":"crossref","unstructured":"Amin MB, Edge SB, Greene FL, Schilsky RL, Gaspar LE, Washington MK, Sullivan DC, Brookland RK (2017) AJCC Cancer Staging Manual. 8th edn. Springer","DOI":"10.1007\/978-3-319-40618-3"},{"key":"3098_CR11","unstructured":"WHO; Bosman FT, Carneiro F, Hruban RH,Theise ND (eds) (2010) WHO Classification of Tumours of the Digestive System. 4th edn. WHO Press, Geneva, Switzerland"},{"key":"3098_CR12","volume-title":"The errors of sampling of the survivorship table reports on public health and medical subjects, vol vol.33","author":"M Greenwood","year":"1926","unstructured":"Greenwood M (1926) The errors of sampling of the survivorship table reports on public health and medical subjects, vol vol.33. Her Majesty\u2019s Stationery Office, London"},{"issue":"3","key":"3098_CR13","doi-asserted-by":"publisher","first-page":"388","DOI":"10.7150\/jca.16804","volume":"8","author":"WZ He","year":"2017","unstructured":"He WZ, Liao FX, Jiang C, Kong PF, Yin CX, Yang Q, Qiu HJ, Zhang B, Xia LP (2017) Primary tumor location as a predictive factor for first-line bevacizumab effectiveness in metastatic colorectal cancer patients. J Cancer 8(3):388\u2013394. \n                    https:\/\/doi.org\/10.7150\/jca.16804","journal-title":"J Cancer"},{"issue":"8","key":"3098_CR14","doi-asserted-by":"publisher","first-page":"1862","DOI":"10.1093\/annonc\/mdx119","volume":"28","author":"N Boeckx","year":"2017","unstructured":"Boeckx N, Koukakis R, Op de Beeck K, Rolfo C, Van Camp G, Siena S, Tabernero J, Douillard JY, Andre T, Peeters M (2017) Primary tumor sidedness has an impact on prognosis and treatment outcome in metastatic colorectal cancer: results from two randomized first-line panitumumab studies. Annals of Oncology : Official Journal of the European Society for Medical Oncology 28(8):1862\u20131868. \n                    https:\/\/doi.org\/10.1093\/annonc\/mdx119","journal-title":"Annals of Oncology : Official Journal of the European Society for Medical Oncology"},{"issue":"32","key":"3098_CR15","doi-asserted-by":"publisher","first-page":"53631","DOI":"10.18632\/oncotarget.19022","volume":"8","author":"DD Cao","year":"2017","unstructured":"Cao DD, Xu HL, Xu XM, Ge W (2017) The impact of primary tumor location on efficacy of cetuximab in metastatic colorectal cancer patients with different KRAS status: a systematic review and meta-analysis. Oncotarget 8(32):53631\u201353641. \n                    https:\/\/doi.org\/10.18632\/oncotarget.19022","journal-title":"Oncotarget"},{"issue":"45","key":"3098_CR16","doi-asserted-by":"publisher","first-page":"79618","DOI":"10.18632\/oncotarget.18896","volume":"8","author":"XF Li","year":"2017","unstructured":"Li XF, Tan YN, Zhong CH, Zhu LZ, Fang XF, Li J, Ding KF, Yuan Y (2017) Left-sided primary tumor is a favorable prognostic factor for metastatic colorectal cancer patients receiving surgery. Oncotarget 8(45):79618\u201379628. \n                    https:\/\/doi.org\/10.18632\/oncotarget.18896","journal-title":"Oncotarget"},{"issue":"20","key":"3098_CR17","doi-asserted-by":"publisher","first-page":"3721","DOI":"10.1200\/JCO.2003.11.122","volume":"21","author":"CH Kohne","year":"2003","unstructured":"Kohne CH, Wils J, Lorenz M, Schoffski P, Voigtmann R, Bokemeyer C, Lutz M, Kleeberg C, Ridwelski K, Souchon R, El-Serafi M, Weiss U, Burkhard O, Ruckle H, Lichnitser M, Langenbuch T, Scheithauer W, Baron B, Couvreur ML, Schmoll HJ, European Organization of R, Treatment of Cancer Gastrointestinal Group S (2003) Randomized phase III study of high-dose fluorouracil given as a weekly 24-hour infusion with or without leucovorin versus bolus fluorouracil plus leucovorin in advanced colorectal cancer: European organization of Research and Treatment of Cancer Gastrointestinal Group Study 40952. J Clin Oncol Off J Am Soc Clin Oncol 21(20):3721\u20133728. \n                    https:\/\/doi.org\/10.1200\/JCO.2003.11.122","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"2","key":"3098_CR18","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1200\/JCO.1997.15.2.808","volume":"15","author":"A Gramont de","year":"1997","unstructured":"de Gramont A, Bosset JF, Milan C, Rougier P, Bouche O, Etienne PL, Morvan F, Louvet C, Guillot T, Francois E, Bedenne L (1997) Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol Off J Am Soc Clin Oncol 15(2):808\u2013815. \n                    https:\/\/doi.org\/10.1200\/JCO.1997.15.2.808","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"16","key":"3098_CR19","doi-asserted-by":"publisher","first-page":"2938","DOI":"10.1200\/JCO.2000.18.16.2938","volume":"18","author":"A Gramont de","year":"2000","unstructured":"de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer G, Papamichael D, Le Bail N, Louvet C, Hendler D, de Braud F, Wilson C, Morvan F, Bonetti A (2000) Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol Off J Am Soc Clin Oncol 18(16):2938\u20132947. \n                    https:\/\/doi.org\/10.1200\/JCO.2000.18.16.2938","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"9209","key":"3098_CR20","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1016\/S0140-6736(00)02034-1","volume":"355","author":"JY Douillard","year":"2000","unstructured":"Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, Jandik P, Iveson T, Carmichael J, Alakl M, Gruia G, Awad L, Rougier P (2000) Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 355(9209):1041\u20131047","journal-title":"Lancet"},{"issue":"13","key":"3098_CR21","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1056\/NEJM200009283431302","volume":"343","author":"LB Saltz","year":"2000","unstructured":"Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta N, Elfring GL, Miller LL (2000) Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group The New England Journal of Medicine 343(13):905\u2013914. \n                    https:\/\/doi.org\/10.1056\/NEJM200009283431302","journal-title":"Irinotecan Study Group The New England Journal of Medicine"},{"issue":"15","key":"3098_CR22","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1200\/JCO.2010.33.5091","volume":"29","author":"E Cutsem Van","year":"2011","unstructured":"Van Cutsem E, Kohne CH, Lang I, Folprecht G, Nowacki MP, Cascinu S, Shchepotin I, Maurel J, Cunningham D, Tejpar S, Schlichting M, Zubel A, Celik I, Rougier P, Ciardiello F (2011) Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol Off J Am Soc Clin Oncol 29(15):2011\u20132019. \n                    https:\/\/doi.org\/10.1200\/JCO.2010.33.5091","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"12","key":"3098_CR23","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1200\/JCO.2007.14.9930","volume":"26","author":"LB Saltz","year":"2008","unstructured":"Saltz LB, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS, Rivera F, Couture F, Sirzen F, Cassidy J (2008) Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol Off J Am Soc Clin Oncol 26(12):2013\u20132019. \n                    https:\/\/doi.org\/10.1200\/JCO.2007.14.9930","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"16","key":"3098_CR24","doi-asserted-by":"publisher","first-page":"3697","DOI":"10.1200\/JCO.2005.05.112","volume":"23","author":"FF Kabbinavar","year":"2005","unstructured":"Kabbinavar FF, Schulz J, McCleod M, Patel T, Hamm JT, Hecht JR, Mass R, Perrou B, Nelson B, Novotny WF (2005) Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol Off J Am Soc Clin Oncol 23(16):3697\u20133705. \n                    https:\/\/doi.org\/10.1200\/JCO.2005.05.112","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"23","key":"3098_CR25","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1056\/NEJMoa032691","volume":"350","author":"H Hurwitz","year":"2004","unstructured":"Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350(23):2335\u20132342. \n                    https:\/\/doi.org\/10.1056\/NEJMoa032691","journal-title":"N Engl J Med"},{"issue":"10","key":"3098_CR26","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1016\/S1470-2045(14)70330-4","volume":"15","author":"V Heinemann","year":"2014","unstructured":"Heinemann V, von Weikersthal LF, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, Heintges T, Lerchenmuller C, Kahl C, Seipelt G, Kullmann F, Stauch M, Scheithauer W, Hielscher J, Scholz M, Muller S, Link H, Niederle N, Rost A, Hoffkes HG, Moehler M, Lindig RU, Modest DP, Rossius L, Kirchner T, Jung A, Stintzing S (2014) FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol 15(10):1065\u20131075. \n                    https:\/\/doi.org\/10.1016\/S1470-2045(14)70330-4","journal-title":"Lancet Oncol"},{"issue":"3","key":"3098_CR27","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1200\/JCO.2007.12.5906","volume":"26","author":"A Lievre","year":"2008","unstructured":"Lievre A, Bachet JB, Boige V, Cayre A, Le Corre D, Buc E, Ychou M, Bouche O, Landi B, Louvet C, Andre T, Bibeau F, Diebold MD, Rougier P, Ducreux M, Tomasic G, Emile JF, Penault-Llorca F, Laurent-Puig P (2008) KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol Off J Am Soc Clin Oncol 26(3):374\u2013379. \n                    https:\/\/doi.org\/10.1200\/JCO.2007.12.5906","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"8","key":"3098_CR28","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1093\/annonc\/mdi246","volume":"16","author":"G Folprecht","year":"2005","unstructured":"Folprecht G, Grothey A, Alberts S, Raab HR, Kohne CH (2005) Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. Annals of Oncology : Official Journal of the European Society for Medical Oncology 16(8):1311\u20131319. \n                    https:\/\/doi.org\/10.1093\/annonc\/mdi246","journal-title":"Annals of Oncology : Official Journal of the European Society for Medical Oncology"},{"issue":"1","key":"3098_CR29","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/S1470-2045(09)70330-4","volume":"11","author":"G Folprecht","year":"2010","unstructured":"Folprecht G, Gruenberger T, Bechstein WO, Raab HR, Lordick F, Hartmann JT, Lang H, Frilling A, Stoehlmacher J, Weitz J, Konopke R, Stroszczynski C, Liersch T, Ockert D, Herrmann T, Goekkurt E, Parisi F, Kohne CH (2010) Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol 11(1):38\u201347. \n                    https:\/\/doi.org\/10.1016\/S1470-2045(09)70330-4","journal-title":"Lancet Oncol"},{"issue":"16","key":"3098_CR30","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1200\/JCO.2012.44.8308","volume":"31","author":"LC Ye","year":"2013","unstructured":"Ye LC, Liu TS, Ren L, Wei Y, Zhu DX, Zai SY, Ye QH, Yu Y, Xu B, Qin XY, Xu J (2013) Randomized controlled trial of cetuximab plus chemotherapy for patients with KRAS wild-type unresectable colorectal liver-limited metastases. J Clin Oncol Off J Am Soc Clin Oncol 31(16):1931\u20131938. \n                    https:\/\/doi.org\/10.1200\/JCO.2012.44.8308","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"4","key":"3098_CR31","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1001\/jamasurg.2013.1216","volume":"148","author":"S Jegatheeswaran","year":"2013","unstructured":"Jegatheeswaran S, Mason JM, Hancock HC, Siriwardena AK (2013) The liver-first approach to the management of colorectal cancer with synchronous hepatic metastases: a systematic review. JAMA Surg 148(4):385\u2013391. \n                    https:\/\/doi.org\/10.1001\/jamasurg.2013.1216","journal-title":"JAMA Surg"},{"issue":"2","key":"3098_CR32","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1159\/000368246","volume":"88","author":"A Wein","year":"2015","unstructured":"Wein A, Emmert M, Merkel S, Harich HD, Siebler J, Thiemann R, Lamberti C, Gottler B, Fries S, Kiani A, Schlag R, Gruner M, Steinbild S, Eberl S, Pohl-Dernick K, Dorje F, Horbach T, Schoffski O, Neurath MF, Hohenberger W (2015) Palliative treatment of colorectal cancer with secondary metastasis resection in Germany\u2014impact of the multidisciplinary treatment approach on prognosis and cost: the northern Bavaria IVOPAK I project. Oncology 88(2):103\u2013121. \n                    https:\/\/doi.org\/10.1159\/000368246","journal-title":"Oncology"},{"issue":"6","key":"3098_CR33","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1007\/s00268-014-2513-3","volume":"38","author":"E Schadde","year":"2014","unstructured":"Schadde E, Ardiles V, Slankamenac K, Tschuor C, Sergeant G, Amacker N, Baumgart J, Croome K, Hernandez-Alejandro R, Lang H, de Santibanes E, Clavien PA (2014) ALPPS offers a better chance of complete resection in patients with primarily unresectable liver tumors compared with conventional-staged hepatectomies: results of a multicenter analysis. World J Surg 38(6):1510\u20131519. \n                    https:\/\/doi.org\/10.1007\/s00268-014-2513-3","journal-title":"World J Surg"},{"issue":"5","key":"3098_CR34","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1097\/SLA.0000000000000947","volume":"260","author":"E Schadde","year":"2014","unstructured":"Schadde E, Ardiles V, Robles-Campos R, Malago M, Machado M, Hernandez-Alejandro R, Soubrane O, Schnitzbauer AA, Raptis D, Tschuor C, Petrowsky H, De Santibanes E, Clavien PA, Group AR (2014) Early survival and safety of ALPPS: first report of the international ALPPS registry. Ann Surg 260(5):829\u2013836; discussion 836-828. \n                    https:\/\/doi.org\/10.1097\/SLA.0000000000000947","journal-title":"Ann Surg"},{"issue":"5","key":"3098_CR35","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1093\/annonc\/mdv037","volume":"26","author":"T Baere de","year":"2015","unstructured":"de Baere T, Auperin A, Deschamps F, Chevallier P, Gaubert Y, Boige V, Fonck M, Escudier B, Palussiere J (2015) Radiofrequency ablation is a valid treatment option for lung metastases: experience in 566 patients with 1037 metastases. Annals of Oncology : Official Journal of the European Society for Med Oncol 26(5):987\u2013991. \n                    https:\/\/doi.org\/10.1093\/annonc\/mdv037","journal-title":"Annals of Oncology : Official Journal of the European Society for Med Oncol"},{"key":"3098_CR36","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1186\/s12957-015-0621-7","volume":"13","author":"JH Cho","year":"2015","unstructured":"Cho JH, Kim S, Namgung M, Choi YS, Kim HK, Zo JI, Shim YM, Kim J (2015) The prognostic importance of the number of metastases in pulmonary metastasectomy of colorectal cancer. World Journal of Surgical Oncology 13:222. \n                    https:\/\/doi.org\/10.1186\/s12957-015-0621-7","journal-title":"World Journal of Surgical Oncology"},{"issue":"2","key":"3098_CR37","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.ejca.2013.09.024","volume":"50","author":"D Elias","year":"2014","unstructured":"Elias D, Goere D, Dumont F, Honore C, Dartigues P, Stoclin A, Malka D, Boige V, Ducreux M (2014) Role of hyperthermic intraoperative peritoneal chemotherapy in the management of peritoneal metastases. Eur J Cancer 50(2):332\u2013340. \n                    https:\/\/doi.org\/10.1016\/j.ejca.2013.09.024","journal-title":"Eur J Cancer"},{"issue":"12","key":"3098_CR38","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1055\/s-0043-121106","volume":"55","author":"W Schmiegel","year":"2017","unstructured":"Schmiegel W, Buchberger B, Follmann M, Graeven U, Heinemann V, Langer T, Nothacker M, Porschen R, Rodel C, Rosch T, Schmitt W, Wesselmann S, Pox C (2017) S3-Leitlinie - Kolorektales Karzinom. Zeitschrift fur Gastroenterologie 55(12):1344\u20131498. \n                    https:\/\/doi.org\/10.1055\/s-0043-121106","journal-title":"Zeitschrift fur Gastroenterologie"},{"issue":"11","key":"3098_CR39","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1056\/NEJMoa1305275","volume":"369","author":"JY Douillard","year":"2013","unstructured":"Douillard JY, Oliner KS, Siena S, Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham D, Jassem J, Rivera F, Kocakova I, Ruff P, Blasinska-Morawiec M, Smakal M, Canon JL, Rother M, Williams R, Rong A, Wiezorek J, Sidhu R, Patterson SD (2013) Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 369(11):1023\u20131034. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1305275","journal-title":"N Engl J Med"},{"issue":"9","key":"3098_CR40","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1016\/S1470-2045(17)30422-9","volume":"18","author":"MJ Overman","year":"2017","unstructured":"Overman MJ, McDermott R, Leach JL, Lonardi S, Lenz HJ, Morse MA, Desai J, Hill A, Axelson M, Moss RA, Goldberg MV, Cao ZA, Ledeine JM, Maglinte GA, Kopetz S, Andre T (2017) Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol 18(9):1182\u20131191. \n                    https:\/\/doi.org\/10.1016\/S1470-2045(17)30422-9","journal-title":"Lancet Oncol"}],"container-title":["International Journal of Colorectal Disease"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00384-018-3098-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00384-018-3098-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00384-018-3098-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,17]],"date-time":"2019-06-17T19:29:35Z","timestamp":1560799775000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00384-018-3098-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,18]]},"references-count":40,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["3098"],"URL":"https:\/\/doi.org\/10.1007\/s00384-018-3098-3","relation":{},"ISSN":["0179-1958","1432-1262"],"issn-type":[{"type":"print","value":"0179-1958"},{"type":"electronic","value":"1432-1262"}],"subject":[],"published":{"date-parts":[[2018,6,18]]},"assertion":[{"value":"8 June 2018","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2018","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}